Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery



Swadi, Rasha ORCID: 0000-0002-0758-9247, Mather, Grace, Pizer, Barry L, Losty, Paul D ORCID: 0000-0003-0841-5879, See, Violaine ORCID: 0000-0001-6384-8381 and Moss, Diana
(2018) Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery. BMC Cancer, 18 (1). 28-.

[thumbnail of Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery.pdf] Text
Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery.pdf - Published version

Download (1MB)

Abstract

Background Neuroblastoma is a paediatric cancer that despite multimodal therapy still has a poor outcome for many patients with high risk tumours. Retinoic acid (RA) promotes differentiation of some neuroblastoma tumours and cell lines, and is successfully used clinically, supporting the view that differentiation therapy is a promising strategy for treatment of neuroblastoma. To improve treatment of a wider range of tumour types, development and testing of novel differentiation agents is essential. New pre-clinical models are therefore required to test therapies in a rapid cost effective way in order to identify the most useful agents. Methods As a proof of principle, differentiation upon ATRA treatment of two MYCN-amplified neuroblastoma cell lines, IMR32 and BE2C, was measured both in cell cultures and in tumours formed on the chick chorioallantoic membrane (CAM). Differentiation was assessed by 1) change in cell morphology, 2) reduction in cell proliferation using Ki67 staining and 3) changes in differentiation markers (STMN4 and ROBO2) and stem cell marker (KLF4). Results were compared to MLN8237, a classical Aurora Kinase A inhibitor. For the in vivo experiments, cells were implanted on the CAM at embryonic day 7 (E7), ATRA treatment was between E11 and E13 and tumours were analysed at E14. Results Treatment of IMR32 and BE2C cells in vitro with 10 μM ATRA resulted in a change in cell morphology, a 65% decrease in cell proliferation, upregulation of STMN4 and ROBO2 and downregulation of KLF4. ATRA proved more effective than MLN8237 in these assays. In vivo, 100 μM ATRA repetitive treatment at E11, E12 and E13 promoted a change in expression of differentiation markers and reduced proliferation by 43% (p < 0.05). 40 μM ATRA treatment at E11 and E13 reduced proliferation by 37% (p < 0.05) and also changed cell morphology within the tumour. Conclusion Differentiation of neuroblastoma tumours formed on the chick CAM can be analysed by changes in cell morphology, proliferation and gene expression. The well-described effects of ATRA on neuroblastoma differentiation were recapitulated within 3 days in the chick embryo model, which therefore offers a rapid, cost effective model compliant with the 3Rs to select promising drugs for further preclinical analysis.

Item Type: Article
Uncontrolled Keywords: Neuroblastoma, Chick embryo, Retinoic acid, Drug delivery, Differentiation therapy, 3Rs, Chorioallantoic membrane
Depositing User: Symplectic Admin
Date Deposited: 12 Jan 2018 10:18
Last Modified: 19 Jan 2023 06:45
DOI: 10.1186/s12885-017-3978-x
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3015919